NCT04098692 - Mass Balance and Pharmacokinetics Study of Derazantinib in Healthy Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 8, 2019

Primary Completion Date

November 18, 2019

Study Completion Date

November 18, 2019

Conditions

Healthy Volunteers

Interventions

DRUG

Derazantinib capsule

300 mg derazantinib oral administration (3x100 mg capsules)

DRUG

[14C]-Derazantinib solution for infusion

100 μg \[14C\]-derazantinib intravenous administration

DRUG

[14C]-Derazantinib capsule

300 mg \[14C\]-derazantinib oral administration (3x100 mg capsules)

Trial Locations (1)

Quotient Sciences, Ruddington, Nottingham